Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.
نویسنده
چکیده
Many prospective studies and a recent randomized controlled trial have shown that the B-cell-depleting monoclonal antibody, rituximab, safely promotes the remission of nephrotic syndrome in approximately 65% of patients with membranous nephropathy (MN). Mechanistic studies have indicated that rituximab-induced proteinuria reduction is associated with clearance of anti-podocyte antigens phospholipase 2 receptor autoantibodies and subepithelial immune complexes, the hallmarks of the disease. A recently published study reported results which, at first sight, looked less favorable and implied that, due to a publication bias against negative results, the efficacy of rituximab in MN might be overestimated. Since patients received only one or 2 rituximab administrations, the authors suggest that when rituximab is used, higher doses and longer treatments should be considered. In this study, we highlight limitations of the study and warn against an oversimplified interpretation of the data. Though information on the optimal dose of rituximab to use in MN is still limited, available data from studies with predefined rituximab administration protocols collectively support the concept of titrating rituximab to the number of circulating B-cells that are invariably depleted after the first or second administration. Additional doses may increase the risk of adverse effects and related costs without augmenting efficacy. Importantly, underpowered studies with inconclusive results should not be confused with negative studies formally proving a neutral effect of a treatment. Until data from ad hoc designed clinical trials are available, the B-cell-driven protocol should be the preferred regimen, since it is similarly effective, but safer and more cost effective than other protocols employing multiple rituximab administrations.
منابع مشابه
Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal
Many prospective studies and a recent randomized controlled trial have shown that the B-cell-depleting monoclonal antibody, rituximab, safely promotes the remission of nephrotic syndrome in approximately 65% of patients with membranous nephropathy (MN). Mechanistic studies have indicated that rituximab-induced proteinuria reduction is associated with clearance of anti-podocyte antigens phosphol...
متن کاملMembranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
INTRODUCTION There is broad consensus that high grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous nephropathy. Based on the fact that current regimens are not ideal due to short and long-term toxicity and propensity to relapse after treatment withdrawal, we developed a treatment protocol ba...
متن کاملRituximab in membranous nephropathy: is it a first-line treatment?
Rituximab, a B cell–depleting anti-CD20 chimeric monoclonal antibody, is Food and Drug Administration approved in the United States for the treatment of certain lymphomas, rheumatoid arthritis, and granulomatous and microscopic polyangiitis. It has been used additionally in a wide variety of glomerular disorders including lupus nephritis, IgA nephropathy, minimal change disease and focal segmen...
متن کاملClinicopathologic features and outcome of membranous nephropathy in Markaz Tebi children hospital
Background and Objectives: This research study was conducted to determine the correlation between the clinicopathologic features and the outcome of membranous nephropathy. Materials and Methods: Data were retrospectively reviewed from all patients with a diagnosis of membranous nephropathy. Demographic, ...
متن کاملTwo cases of idiopathic membranous nephropathy treated with rituximab
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has been reported as a cause of idiopathic primary glomerulonephropathy in up to 90% of patients. However, the treatment options remain controversial. We report two cases of idiopathic membranous nephropathy that were treated with rituximab. A 54-year-old man and a 64-year old man were admitted for rituximab therapy....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephron
دوره 135 1 شماره
صفحات -
تاریخ انتشار 2017